多发性硬化症的疾病修正疗法：概述与治疗考量
Disease-Modifying Therapies in Multiple Sclerosis: Overview and Treatment Considerations.
作者信息
Robertson Derrick, Moreo Natalie
机构信息
is director of the Multiple Sclerosis Center of Excellence at James A. Haley Veterans' Hospital in Tampa, Florida. is a PGY-1 multiple sclerosis fellow, and Dr. Robertson is an assistant professor of neurology and director of the multiple sclerosis division, both at the University of South Florida in Tampa.
出版信息
Fed Pract. 2016 Jun;33(6):28-34.
Abstract
Controlling symptoms can slow the physical and emotional disabilities associated with multiple sclerosis and help patients attain the highest quality of life possible for as long as possible.
摘要
控制症状可以减缓与多发性硬化症相关的身体和情感残疾，并帮助患者尽可能长时间地获得最高质量的生活。
相似文献
1
Disease-Modifying Therapies in Multiple Sclerosis: Overview and Treatment Considerations.多发性硬化症的疾病修正疗法：概述与治疗考量
Fed Pract. 2016 Jun;33(6):28-34.
2
A prospective web-based patient-centred interactive study of long-term disabilities, disabilities perception and health-related quality of life in patients with multiple sclerosis in The Netherlands: the Dutch Multiple Sclerosis Study protocol.荷兰一项基于网络的前瞻性以患者为中心的互动研究，涉及多发性硬化症患者的长期残疾、残疾认知及健康相关生活质量：荷兰多发性硬化症研究方案
BMC Neurol. 2015 Aug 4;15:128. doi: 10.1186/s12883-015-0379-0.
3
Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice.临床实践中口服与注射用多发性硬化症疾病修正治疗的疗效和耐受性
Mult Scler J Exp Transl Clin. 2016 Jan-Dec;2. doi: 10.1177/2055217316677868. Epub 2016 Nov 1.
4
[Immunomodulatory therapy in multiple sclerosis].[多发性硬化症的免疫调节治疗]
Ideggyogy Sz. 2004 Nov 20;57(11-12):401-16.
5
Considerations for the development of a physical activity guide for Canadians with physical disabilities.为身体残疾的加拿大人制定身体活动指南的考量因素。
Can J Public Health. 2007;98 Suppl 2:S135-47.
6
Balancing Early Aggression Against Risk of Progression in Multiple Sclerosis.平衡多发性硬化症早期积极治疗与疾病进展风险
Can J Neurol Sci. 2016 Jan;43(1):33-43. doi: 10.1017/cjn.2015.302. Epub 2015 Nov 27.
7
Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis.注射用干扰素β-1a、注射用重组人干扰素β-1b 和干扰素β-1a 注射液治疗多发性硬化对生活质量的影响。
Psychiatry Clin Neurosci. 2015 Oct;69(10):649-57. doi: 10.1111/pcn.12308. Epub 2015 Jun 1.
8
Multiple Sclerosis: Clinical Updates in Women's Health Care Primary and Preventive Care Review.多发性硬化症：女性健康照护初级与预防保健回顾中的临床新进展。
Obstet Gynecol. 2020 Mar;135(3):757-758. doi: 10.1097/AOG.0000000000003727.
9
Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm.早期和晚期多发性硬化症的疾病修正治疗：一种新的治疗模式。
Curr Opin Neurol. 2018 Jun;31(3):233-243. doi: 10.1097/WCO.0000000000000561.
10
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.复发型多发性硬化症中疾病修正疗法的顺序：安全性和免疫学考虑。
J Neurol. 2017 Dec;264(12):2351-2374. doi: 10.1007/s00415-017-8594-9. Epub 2017 Sep 6.
引用本文的文献
1
Circulating cell-free DNA methylation profiles as noninvasive multiple sclerosis biomarkers: A proof-of-concept study.循环游离DNA甲基化谱作为非侵入性多发性硬化症生物标志物：一项概念验证研究。
medRxiv. 2025 Feb 20:2025.02.14.25322180. doi: 10.1101/2025.02.14.25322180.
2
An updated systematic review and meta-analysis exploring the efficacy and safety of dimethyl fumarate (DMF) for patients with multiple sclerosis (MS).一项最新的系统评价和荟萃分析，探讨富马酸二甲酯（DMF）对多发性硬化症（MS）患者的疗效和安全性。
BMJ Neurol Open. 2024 Dec 18;6(2):e000872. doi: 10.1136/bmjno-2024-000872. eCollection 2024.
3
Pyroptosis the Emerging Link Between Gut Microbiota and Multiple Sclerosis.细胞焦亡：肠道微生物群与多发性硬化症之间新发现的联系
Drug Des Devel Ther. 2024 Dec 19;18:6145-6164. doi: 10.2147/DDDT.S489454. eCollection 2024.
4
Hyperresponsiveness of Corticoid-Resistant Th17/Tc-17 Cells to TLR-2 and TLR-4 Ligands is a Feature of Multiple Sclerosis Patients at Higher Risk of Therapy Failure.皮质激素抵抗性Th17/Tc-17细胞对TLR-2和TLR-4配体的高反应性是多发性硬化症患者治疗失败风险较高的一个特征。
J Inflamm Res. 2024 Nov 14;17:8775-8797. doi: 10.2147/JIR.S476110. eCollection 2024.
5
The Probable Infectious Origin of Multiple Sclerosis.多发性硬化症可能的感染起源
NeuroSci. 2023 Sep 7;4(3):211-234. doi: 10.3390/neurosci4030019. eCollection 2023 Sep.
6
Eyes as Windows: Unveiling Neuroinflammation in Multiple Sclerosis via Optic Neuritis and Uhthoff's Phenomenon.眼睛如窗口：通过视神经炎和乌托夫现象揭示多发性硬化症中的神经炎症
Diagnostics (Basel). 2024 Oct 2;14(19):2198. doi: 10.3390/diagnostics14192198.
7
The Effects of Epigallocatechin-3-Gallate Nutritional Supplementation in the Management of Multiple Sclerosis: A Systematic Review of Clinical Trials.表没食子儿茶素没食子酸酯营养补充剂治疗多发性硬化症的效果：临床试验的系统评价。
Nutrients. 2024 Aug 15;16(16):2723. doi: 10.3390/nu16162723.
8
Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study.基于机器学习预测多发性硬化症的残疾进展：一项观察性、国际性、多中心研究。
PLOS Digit Health. 2024 Jul 25;3(7):e0000533. doi: 10.1371/journal.pdig.0000533. eCollection 2024 Jul.
9
ACKR3 Antagonism Enhances the Repair of Demyelinated Lesions Through Both Immunomodulatory and Remyelinating Effects.ACKR3 拮抗剂通过免疫调节和髓鞘修复作用增强脱髓鞘病变的修复。
Neurochem Res. 2024 Aug;49(8):2087-2104. doi: 10.1007/s11064-024-04173-1. Epub 2024 May 31.
10
Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.临床研究证据表明，疾病修正疗法对多发性硬化症的生活质量有影响：系统分析。
J Neurol. 2024 Jun;271(6):3131-3141. doi: 10.1007/s00415-024-12366-5. Epub 2024 Apr 16.
本文引用的文献
1
A basic overview of multiple sclerosis immunopathology.多发性硬化症免疫病理学的基本概述。
Eur J Neurol. 2015 Oct;22 Suppl 2:3-13. doi: 10.1111/ene.12798.
2
Peripheral blood biomarkers in multiple sclerosis.多发性硬化症的外周血生物标志物。
Autoimmun Rev. 2015 Dec;14(12):1097-110. doi: 10.1016/j.autrev.2015.07.014. Epub 2015 Jul 28.
3
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?美国多发性硬化症药物的成本与制药行业：规模太大而不能倒？
Neurology. 2015 May 26;84(21):2185-92. doi: 10.1212/WNL.0000000000001608. Epub 2015 Apr 24.
4
Optimizing multiple sclerosis diagnosis: gene expression and genomic association.优化多发性硬化症的诊断：基因表达与基因组关联。
Ann Clin Transl Neurol. 2015 Mar;2(3):271-7. doi: 10.1002/acn3.174. Epub 2015 Feb 6.
5
Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse.多发性硬化症的治疗优化：一项关于治疗依从性和复发风险的队列研究。
Mult Scler Relat Disord. 2015 Jan;4(1):75-82. doi: 10.1016/j.msard.2014.09.214. Epub 2014 Oct 7.
6
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.儿童多发性硬化症：临床诊断、治疗策略和研究的最新进展。
Lancet Neurol. 2014 Sep;13(9):936-48. doi: 10.1016/S1474-4422(14)70093-6.
7
Defining the clinical course of multiple sclerosis: the 2013 revisions.多发性硬化症临床病程的定义：2013年修订版
Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.
8
Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.聚乙二醇干扰素 β-1a 治疗复发缓解型多发性硬化症（ADVANCE）：一项随机、3 期、双盲研究。
Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30.
9
Multiple sclerosis in New Zealand.新西兰的多发性硬化症
J Clin Neurosci. 2014 Aug;21(8):1288-91. doi: 10.1016/j.jocn.2013.09.009. Epub 2013 Nov 4.
10
Multiple sclerosis in children and adolescents: incidence and clinical picture - new insights from the nationwide German surveillance (2009-2011).儿童和青少年多发性硬化症：发病率和临床特征-来自全国性德国监测（2009-2011）的新见解。
Eur J Neurol. 2014 Apr;21(4):654-9. doi: 10.1111/ene.12371. Epub 2014 Jan 28.
Zotero 插件